Observations placeholder
Votrient
Identifier
020377
Type of Spiritual Experience
Background
A description of the experience
Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma.
Adverse effects
The most common side effects of pazopanib are nausea, vomiting, diarrhoea (occurs in about half of patients), changes in hair colour, hypertension (which usually occurs during the first few weeks of treatment), appetite loss, hyperglycaemia, hypoglycaemia, electrolyte abnormalities (including hypocalcaemia, hypomagnesemia, hypophosphatemia), lab anomalies (including increased AST, ALT and protein in the urine), oedema, hair loss or discolouration, taste changes, abdominal pain, hypertension, rash, fatigue and myelosuppression (including leucopenia, neutropenia, thrombocytopenia and lymphopenia) It has been associated with a low, but real risk of potentially fatal liver damage
On Dec, 25, 2016 11,154 people reported to have side effects when taking Votrient.
Among them, 7 people (0.06%) have Hallucination
On Jan, 27, 2016: 2,076 people reported to have side effects when taking Votrient. Among them, 301 people (14.50%) have Death.
Time on Votrient when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 32.73% | 56.36% | 9.09% | 1.82% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Votrient :
| Female | Male | |
| Death | 26.71% | 73.29% |
Age of people who have Death when taking Votrient :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 1.54% | 1.03% | 2.56% | 10.26% | 21.03% | 63.59% |